tbuckley/cabot-search huggingface dataset:
Erratum: Cerebral palsy
Authors: H. Kerr Graham, Peter Rosenbaum, Nigel Paneth, Bernard Dan, Jean-Pierre Lin, Diane L. Damiano, Jules G. Becher, Deborah Gaebler-Spira, Allan Colver, Dinah S. Reddihough, Kylie E. Crompton, Richard L. Lieber
Journal: Nature Reviews Disease Primers (2016)
Body Composition and Cardiovascular Events in Patients With Colorectal Cancer
Authors: Justin C. Brown, Bette J. Caan, Carla M. Prado, Erin Weltzien, Jingjie Xiao, Elizabeth M. Cespedes Feliciano, Candyce H. Kroenke, Jeffrey A. Meyerhardt
Journal: JAMA Oncology (2019)

Patients with colorectal cancer (CRC) are up to 4-fold more likely than individuals without a history of cancer to develop cardiovascular disease. Clinical care guidelines recommend that physicians counsel patients with CRC regarding the association between obesity (defined using body mass index [BMI] calculated as weight in kilograms divided by height in meters squared) and cardiovascular disease risk; however, this recommendation is based on expert opinion.
Pathological complete response rates following neoadjuvant systemic therapy in 300 patients with early or locally advanced HER2 positive breast cancer: The Royal Marsden experience
Authors: N. Chaabouni, N.M.L. Battisti, V. True, N.R. Chopra, S.T.C. Shepherd, K. Lee, R. Joshi, M. Kabir, M. Allen, A. Ring
Journal: Annals of Oncology (2019)

Background: Neoadjuvant chemotherapy plus anti-HER2 treatment is increasingly becoming the treatment of choice for all but the lowest risk HER2+ early and locally advanced breast cancer (BC). Patients achieving a pathological complete response (pCR) have substantially better outcomes compared with non-pCR. We evaluated the pCR rates following neoadjuvant systemic therapy in our HER2+ BC population and determined the influence of tumour and patient characteristics, and adverse events on pCR rates, disease free survival (DFS) and overall survival (OS). Methods: We retrospectively identified patients with early and locally advanced HER2+ BC who received neoadjuvant treatment from January 2013 to December 2017 and underwent subsequent surgery. pCR was defined as ypT0/is N0. Demographics, patient and disease characteristics, pathological responses, toxicities, dose delays and reductions were recorded. Statistical analysis was undertaken using Chi-squared, Kaplan Meier and Log-rank tests. Results: 300 patients were identified. Median age was 51 years (range 25-78) and 286 (95.3%) patients had performance status (PS) 0. 11 (4.0%) patients had clinical stage I, 189 (63.0%) stage II and 100 (33.0%) stage III disease. 204 (68.0%) had grade 3 disease and 282 (94.0%) ductal histology. 185 (61.7%) patients had ER+ disease and 115 (38.3%) ER- disease. 155 (52.0%) patients were treated with chemotherapy plus Trastuzumab. 143 (48.0%) patients had chemotherapy plus Trastuzumab and Pertuzumab. pCR rate in the overall population was 54.3% and significantly better in the ER- compared with the ER+ subgroup (68.7 vs 45.4 %; p < 0.001). Patients on dual anti-HER2 blockade achieved higher pCR rates compared with those on Trastuzumab (56.6 vs 52.2%) although the difference was not statistically significant (p = 0.448). pCR rates were not influenced by age, PS, dose reductions or dose delays but were significantly lower in case of chemotherapy early discontinuation. With a median follow-up of 23 months, median DFS and OS were not reached. Conclusions: In our analysis, pCR rate was similar to published data in the literature and was higher in the ER-/HER2 positive subgroup. Legal entity responsible for the study: The Breast Unit, The Royal Marsden Hospital. Funding: Has not received any funding. Disclosure: All authors have declared no conflicts of interest.
A pragmatic, randomised, multicentre trial comparing 4-weekly vs. 12-weekly administration of bone-targeted agents (denosumab, zoledronate or pamidronate) in patients with bone metastases
Authors: M. Clemons, C. Stober, M. Mates, A.A. Joy, A. Robinson, J. Hilton, P. Blanchette, O. Aseyev, G. Pond, D. Fergusson
Journal: Annals of Oncology (2019)

Defining the optimal dosing interval of bone-targeted agents (BTAs), such as denosumab (DN) and bisphosphonates, for patients (pts) with bone metastases remains an important clinical question. We performed a pragmatic randomised trial comparing the non-inferiority of 12- vs. 4-weekly BTAs in pts with breast and prostate cancer. We present data from the breast cohort. Breast cancer pts who were either BTA-naïve, or already receiving, DN, zoledronate (ZA) or pamidronate (PAM) were eligible. They were randomised to their chosen BTA every 12- or 4-weeks for one year. The primary endpoint was Health Related Quality of Life (HRQL) (EORTC-QLQ-C30 Functional Domain-Physical Subdomain). Secondary endpoints included: pain (EORTC-QLQ-BM22-pain domain), Global Health Status (EORTC-QLQ-C30), symptomatic skeletal event (SSE) rates and SSE-free survival (composite of time to first SSE and time to death). Adverse events and toxicity were also compared. Of 160 breast cancer pts, 79 (49.4%) were randomised to 12- and 81 (50.6%) to 4-weekly therapy. 64 pts (40%) were BTA naïve. BTAs included; DN (n = 60, 37.5%), ZA (n = 48, 30%) or PAM (n = 52, 32.5%). Study-reported outcomes showed no significant difference in change from baseline in: HRQL-physical domain (median [range]: 0 [-87,20] vs. 0 [-66,53]), pain (median [range]: 0 [-80,33] vs. 0 [-27,20]), Global Health Status (median [range]: 0 [-67,50] vs. 0 [-50,42]) between the 12- and 4-weekly arms, respectively. Five (6%) and 7 (9%) pts had an SSE within 2 years and 1-year SSE-free survival was 65% (95% CI:52-75%) and 80% (69-88%) in the 12- and 4-weekly arms, respectively. Changes in dosing schedules were more common in the 4-weekly arm (17% vs 31%). Results were similar for subgroup analyses for BTA naïve and pre-treated pts, and for pts receiving DN, ZA or PAM. The findings of this trial are consistent with those previously reported for de-escalating ZA. This trial also included pts receiving de-escalated DN and PAM. While the results of the REDUSE trial are awaited, the data presented would suggest that de-escalation of commonly used BTAs is a reasonable treatment option.
IMPACT OF ANTIPLATELET USE ON THE RISK OF BLEEDING AFTER ENDOSCOPIC SUBMUCOSAL DISSECTION FOR GASTRIC ADENOMA AND EARLY GASTRIC CANCER
Authors: YW Chang, JY Jang, JW Kim, SW Han, SH Park
Journal: Endoscopy (2019)

It has been reported that the rate of bleeding after gastric endoscopic submucosal dissection (ESD) is 0.6 – 26.9%. Recently, as the prevalence of cardiovascular disease increases, the frequency of performing ESD is common in patients taking antiplatelet agents. We aimed to evaluate the rate of bleeding after ESD and the risk of thromboembolic events after cessation of antiplatelet agents, and to determine the optimal time of drug cessation.
Короткоцепочечные жирные кислоты: роль в развитии синдрома раздраженного кишечника
Authors: Yu.M. Stepanov, I.Ya. Budzak, I.A. Klenina
Journal: GASTROENTEROLOGY (2019)

В статье рассматриваются вопросы патогенеза синдрома раздраженного кишечника. Проведен короткий анализ вероятных факторов развития синдрома раздраженного кишечника. Отдельно рассмотрена роль кишечной микрофлоры и вклад короткоцепочечных жирных кислот в процессы, происходящие при синдроме раздраженного кишечника. Проанализованы исследования различных авторов относительно короткоцепочечных жирных кислот. Показаны результаты собственных исследований, в которых опеределялось содержание в кале короткоцепочечных жирных кислот у больных с синдромом раздраженного кишечника. Было выявлено существенное повышение содержания короткоцепочечных жирных кислот, особенно при диарейной форме синдрома раздраженного кишечника.
THE EFFECTIVENESS OF ORAL PHLOROGLUCIN AS PREMEDICATION FOR NON-SEDATIVE ESOPHAGOGASTRODUODENOSCOPY: A DOUBLE BLINDED, PLACEBO-CONTROLLED, RANDOMIZED CONTROLLED TRIAL
Authors: KB Cho, YJ Lee, JY Lee, HJ Lee, KS Park
Journal: Endoscopy (2019)

Antispasmotic agents are commonly injected before esophagogastroduodenoscopy (EGD) to inhibit gastrointestinal peristalsis. This study aimed to evaluate the effectiveness of oral Phloroglucin (Flospan) as premedication for non-sedative EGD.
THU-193-4 week treatment for hepatitis C: A randomized controlled trial (4RIBC)
Authors: Lone Wulff Madsen, Anne Ovrehus, Jan Gerstoft, Nina Weis, Toke Seierøe Barfod, Alex Laursen, Henrik Krarup, Anja Ernst, Peer Brehm Christensen
Journal: Journal of Hepatology (2019)
INTRODUCTION OF A DOUBLE-VERIFICATION CHECKLIST FOR ENDOSCOPY PATHOLOGY SAMPLES: A QUALITY IMPROVEMENT PROJECT
Authors: C Murphy, M Murray, P Wieneke
Journal: Endoscopy (2019)

Improvement of patient safety and quality in endoscopy is of utmost importance. Of late, more emphasis has been placed on improvement of technical skills and key performance indicators than examining non-technical skills and human factors for error. In Bantry General Hospital (BGH) there was high number of pathology specimens taken at endoscopy rejected for analysis due to specimen mislabeling. This represented a major breach of patient safety. A Quality improvement (QI) project was undertaken within the endoscopy department using the PDSA approach with the aim of error reduction.
Single UM171 Expanded Cord Blood Permits Transplantation of Better HLA Matched Cords with Excellent Gvhd Relapse Free Survival
Authors: Sandra Cohen, Jean Roy, Silvy Lachance, Anne Marinier, Jean-Sébastien Delisle, Denis-Claude Roy, Lambert Busque, Imran Ahmad, Nadia M. Bambace, Frederic Barabe, Léa Bernard, Thomas L. Kiss, Philippe Bouchard, Pierre Caudrelier, Fannie Larochelle, Sébastien Lemieux, Mégane Tanguay, Jalila Chagraoui, Peter W. Zandstra, Guy Sauvageau
Journal: Blood (2018)
Introducing JAMA Network Insights
Authors: Dost Öngür
Journal: JAMA Psychiatry (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Psychiatry HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Psychiatry journal
Acute Kidney Injury Related to Sepsis—Reply
Authors: Matthieu Legrand, John A. Kellum
Journal: JAMA (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
UNDERWATER ENDOSCOPIC MUCOSAL RESECTION FOR SMALL RECTAL NEUROENDOCRINE TUMORS
Authors: L Coutinho, O Okazaki, C Casamali, L Lenz, C Pennacchi, E Baba, C Gusmon, B Martins, M Cavalcante, F Kawaguti, A Ribeiro, G Andrade, M Simas, R Uemura, S Geiger, F Maluf
Journal: Endoscopy (2019)

Neuroendocrine tumors arise from enterochromaffin cells. The rectum is one of the most commonly sites. Many techniques for resection of rNETs have been reported. UEMR is a technique in which the bowel lumen is filled with water and the lesion is then resected without requiring submucosal injection. Current published guidelines recommend local endoscopic resection for small rNETs with no risk factors for metastasis. However, no clear indications for type of endoscopic intervention exist. This study aimed to evaluate the efficacy and safety of UEMR in removing small rNETs.
ENDOSCOPIC RADIOFREQUENCY ABLATION FOR EXTRAHEPATIC MALIGNANT BILIARY OBSTRUCTION: SAFETY AND EFFICACY OF A SINGLE CENTER ESPERIENCE
Authors: G de Nucci, E Domenico Mandelli, D Redaelli, R Reati, D Morganti, G Manes
Journal: Endoscopy (2019)

Malignant biliary obstruction is often secondary to pancreatic cancer or cholangiocarcinoma. Most of patients present at advanced stage with a short life expectancy and no chance of resolutive therapy. patients with ingravescent icterus, endoscopic drainage is performed with position of metal or plastic biliary stents. Radiofrequency ablation (RFA) have already been studied to improve stent patency and to treat liver lesions percutaneous via. The aim of our study is to assess efficacy and safety of RFA ablation in patients unfit for surgery with malignant biliary obstruction due to extrahepatic colangiocarcinoma.
ENDOCUFF VISION ASSISTED VERSUS STANDARD POLYP RESECTION IN THE COLORECTUM: A PROSPECTIVE RANDOMIZED STUDY (EVASTA STUDY)
Authors: M Hasenöhrl, G Figura, B Haller, M Abdelhafez, C Schlag, RM Schmid, S Delius, P Klare
Journal: Endoscopy (2019)

Cap assisted colonoscopy (CAC) is frequently used in order to facilitate adenoma detection during endoscopy. However, data on how cap assistance influences resection of polyps is scarce. We aimed to evaluate the impact of a cap assistance (Endocuff vision device, EVD) on the resection time of colorectal polyps in patients undergoing routine colonoscopy.
Abstract 15412: Novel Treatment of Hypertension by Specifically Targeting E2F for the Restoration of Endothelial Dihydrofolate Reductase and eNOS Function Under Oxidative Stress
Authors: Hong Li, Qiang Li, Yixuan Zhang, Bo Gu, Taro Narumi, Kin L Siu, JiYoun Youn, Peiqing Liu, Hua Cai
Journal: Circulation (2018)

We have previously shown that hydrogen peroxide (H2O2) downregulates the tetrahydrobiopterin (H4B) salvage enzyme dihydrofolate reductase (DHFR) to result in eNOS uncoupling and elevated blood pres...
Transition Planning for the Senior Surgeon
Authors: Todd K. Rosengart, Gerard Doherty, Robert Higgins, Melina R. Kibbe, Anne C. Mosenthal
Journal: JAMA Surgery (2019)

Aging is well documented to be associated with declines in cognitive function and psychomotor performance, but only limited guidance is currently available from medical professional societies or regulatory agencies on how to translate these observations into the appropriate monitoring of physician performance.The Society of Surgical Chairs conducted a panel discussion at its 2017 annual meeting and a subsequent survey of its membership in 2018 to develop recommendations for the transitioning of the senior surgeon.Recommendations include mandatory cognitive and psychomotor testing of surgeons by at least age 65 years, potentially as a component of ongoing professional practice evaluation; career transition discussions with surgeons beginning early in their careers; respectful consideration of the potential financial needs, long-standing work commitments, and work-life concerns of retiring surgeons; and creation of teaching, mentoring or coaching, and/or administrative opportunities for senior surgeons in modified clinical or nonclinical roles. Ideally, these initiatives will catalyze a thoughtful and comprehensive new vista in supporting an aging workforce while ensuring the safety of patients, the efficient management of health care organizations, and the avoidance of unnecessary depletions to a sufficiently sized cadre of physicians with case-specific competencies.
SCAR-ENGAGED COLORECTAL LESIONS: ENDOSCOPIC SUBMUCOSAL DISSECTION (ESD) VERSUS A HYBRID RESECTION TECHNIQUE (ENDOSCOPIC UNSCARRING MUCOSAL RESECTION – EUMR)
Authors: F Azzolini, P Cecinato, F Calabrese, G Dell'Anna, D Esposito, G Francesco Bonura, R Zecchini, V Iori, G Sereni, M Cavina, S Grillo, E Viale, L Fanti, A Ianniello, PA Testoni, R Sassatelli
Journal: Endoscopy (2019)

Scar-engaged colorectal lesions are characterized by absent or inadequate submucosal lifting, posing a serious challenge for curative resection with need for surgery. We propose a hybrid resection technique that we called Endoscopic Unscarring Mucosal Resection consisting in marking, incision, partial dissection, creation of mucosal flaps and snaring until complete removal of the lesion (en bloc or piecemeal depending on size).
PAPILLARY CANNULATION FACILITATED BY SUBMUCOSAL SALINE INJECTION INTO THE INTRADIVERTICULAR PAPILLA
Authors: SM Park
Journal: Endoscopy (2019)

Endoscopic retrograde cholangiopancreatography (ERCP) of the intradiverticular papilla with an invisible orifice remains challenging. Several techniques have been introduced for everting the papillary opening to facilitate cannulation.
Evaluation of Cxbladder and Adjudication of Atypical Cytology and Equivocal Cystoscopy
Authors: Badrinath Konety, Neal Shore, Andrew Karim Kader, Sima Porten, Siamak Daneshmand, Tony Lough, Yair Lotan
Journal: European Urology (2019)

Cxbladder diagnostic tests combine genomic information from urinary mRNA with phenotypic information to either rule out low-risk individuals or identify patients at a high risk of urothelial carcinoma (UC).To evaluate the performance of Cxbladder and urine cytology, and Cxbladder's adjudication of atypical cytology and equivocal cystoscopy.This is a retrospective analysis of pooled data from three prospective Cxbladder clinical trials and one real-world clinical study. Physicians were blinded to Cxbladder results, and Cxbladder providers were blinded to clinical results. This study analyzed diverse urology practices in the USA, Australia, and New Zealand. A total of 1784 consecutive, prospectively recruited patients with hematuria or previously diagnosed UC provided 852 samples with both local cytology and Cxbladder results; 153 had atypical cytologies and 14 had both atypical cytology and equivocal cystoscopy.Negative predictive value (NPV) and proportion of tumors missed for Cxbladder and local cytology, and evaluation of Cxbladder for adjudicating atypical cytology and equivocal cystoscopy.Cxbladder ruled out 35% of patients and NPV 97% (95% confidence interval [CI] 94-98%) compared with 93% (95% CI 91-94%) for cytology; Cxbladder missed 8.5% and cytology missed 63% of tumors. UC was diagnosed in 26/153 cases of atypical cytology (17%). Cxbladder correctly adjudicated all these patients including those with both atypical cytology and equivocal cystoscopy; these patients had a positive Cxbladder result and were diagnosed with UC by pathology. The incidence of patients with both atypical cytology and equivocal cystoscopy is low.Cxbladder correctly adjudicated all patients diagnosed with UC among those with atypical cytology and equivocal cystoscopy, and outperformed cytology for accurately identifying patients who do not have UC.Cxbladder accurately rules out patients who do not have cancer, and adjudicates cytology and cystoscopy with inconclusive results, minimizing the need for patients to undergo further unnecessary tests and procedures.
Ductal carcinoma in situ of the breast: Immune cell composition according to subtype
Authors: M.C. Agahozo, M.R. Van Bockstal, F.H. Groenendijk, T.P.P. van den Bosch, P. Westenend, C.H.M. van Deurzen
Journal: Annals of Oncology (2019)

Background: Ductal carcinoma in situ (DCIS) of the breast includes several subtypes with a divergent biological behavior. Data regarding the composition of DCIS-associated immune cells and their potential role in DCIS progression is limited. We studied DCIS-associated immune response by characterizing immune cell subsets according to DCIS subtypes. Methods: DCIS-associated tumor infiltrating lymphocyte (TIL) density and distribution were evaluated based on H&E stained sections of excision specimens from 473 patients with DCIS. These cases were subtyped based on ER, PR and HER2. Patients were categorized as TIL-high or TIL-low. The DCIS-associated immune cells of TIL-high cases were immunostained on consecutive whole slides with CD4 (T-helper cells), CD8 (cytotoxic T-cells), CD20 (B-cells), CD68 (macrophages), FOXP3 (regulatory T-cells), PD-L1 (immune checkpoint ligand, clones SP142 and SP263). Results: In total, 131/473 patients (27.7%) were considered as TIL-high and the percentage of TIL-high cases was significantly associated with DCIS subtype (11.4% of ER+PR+/-HER2-, 38.8% of ER+PR+/-HER2+, 61.2% of ER-PR-HER2+ and 63.6% of the TN subtype, P < 0.0001). There was no statistical difference in the immune cell composition according to DCIS subtypes. However, individual DCIS subtype comparison showed that the ER+PR+/-HER2+ subtype was associated with a significantly higher proportion of CD8+ T-cells compared to the TN subtype (P = 0.047). The ER-PR-HER2+ subtype was associated with a higher proportion of CD4+ T cells compared to the TN subtype, though significance was not reached (P = 0.061). PD-L1 expression by both clones was low. However, the mean value of PD-L1 SP263 was higher compared to PD-L1 SP142, for both TILs and tumor cells (P < 0.0001). Conclusions: High numbers of TILs are mainly observed in HER+ and TN DCIS subtypes. The ER+ HER2+ DCIS subtype attracts more CD8+ T-cells compared to the TN subtype. This suggests a more pronounced anti-tumor immunity in HER2+ DCIS, which could play a role in its biological behavior. Legal entity responsible for the study: Erasmus Medical Center Cancer Insitute, the Department of Pathology. Funding: Roche. Disclosure: All authors have declared no conflicts of interest.